

The subtype-specific features of *EVI1* and *PRDM16* in acute myeloid leukemia

We read with interest the response "The closely related rare and severe acute myeloid leukemias carrying *EVI1* or *PRDM16* mutations share singular biological features" by Eveillard *et al.*¹ to our recent publication.² *EVI1* and *PRDM16* belong to the Prdm family, which is characterized by an N-terminal PR domain with multiple zinc fingers. Prdm family members control gene expression through




Figure 1. Expression of *EVI1* and *PRDM16* in different subtypes of AML cells and hematopoietic cell populations derived from the HemaExplorer website (<http://servers.binf.ku.dk/hemaexplorer/>). Both *EVI1* and *PRDM16* are highly expressed in hematopoietic stem cells. *EVI1*, but not *PRDM16*, is up-regulated in some *MLL*-rearranged leukemia. HSC_BM: hematopoietic stem cells from bone marrow; early HPC_BM: hematopoietic progenitor cells from bone marrow; CMP: common myeloid progenitor cell; GMP: granulocyte monocyte progenitors; MEP: megakaryocyte-erythroid progenitor cell; PM_BM: promyelocyte from bone marrow; MY_BM: myelocyte from bone marrow; PMN_BM: polymorphonuclear cells from bone marrow; PMN_PB: polymorphonuclear cells from peripheral blood; mDC: myeloid dendritic cells; pDC: plasmacytoid dendritic cells.

modification of the chromatin state. It has been shown that *EVI1* and *PRDM16* have similar functions in normal and malignant hematopoiesis.^{3,4} They both cause acute myeloid leukemia (AML), and loss of either leads to severe defects of hematopoietic stem cell (HSC) activity. Here, we would like to clarify similarities and differences of *EVI1* and *PRDM16* as poor prognosis biomarkers in AML.

Eveillard *et al.* provide evidence that *EVI1*- and *PRDM16*-rearranged AML share many features including micromegakaryocytes, multilineage dysplasia, and low myeloperoxidase (MPO)-expressing blasts. Given the critical role of *Evi1* and *Prdm16* to maintain HSCs,^{5,6} the low expression of MPO probably indicates the undifferentiated stem cell-like properties of these types of leukemia. Eveillard *et al.* also showed that rearrangements of these genes are associated with inferior survival, and are frequently found in patients with secondary AML. These findings, together with those in previous reports,^{3,4} suggest that both *EVI1* and *PRDM16* are activated by chromosomal rearrangements, confer a poor prognosis presumably by promoting stem cell program in leukemia cells, and are involved in the development of secondary AML. It should be noted, however, that another study found only *EVI1*-rearrangement is associated with monosomy 7, while *PRDM16*-rearrangement had no preferential association with other cytogenetic abnormalities.⁷ Therefore, there may be some mechanistic differences between *EVI1*- and *PRDM16*-induced leukemogenesis. In addition, whether high expressions of *EVI1* and *PRDM16* are independent prognostic factors even in secondary AML remains to be elucidated.

High expressions of *EVI1* and *PRDM16* are also found in a subgroup of AML patients without translocations of these gene loci. We and others have previously shown that *EVI1* is a poor prognostic factor in *MLL*-rearranged AML.² *PRDM16* was also shown to be a transcriptional target of *MLL*,⁸ but interestingly, *PRDM16* is not up-regulated in *MLL*-rearranged AML according to the HemaExplorer⁹ website (<http://servers.binf.ku.dk/hemaexplorer/>) (Figure 1). Furthermore, a very recent report showed the mutually exclusive expression of *EVI1* and *PRDM16* in AMLs without obvious translocation.¹⁰ High *EVI1* expression was mainly detected in *MLL*-rearranged AML and megakaryocytic-lineage AML, while high *PRDM16* expression was detected in myelocytic-lineage AML and myelomonocytic-lineage AML without *MLL*-rearrangements. Thus, it appears that *PRDM16* is up-regulated through different mechanisms from those for *EVI1* in AML patients. Further investigation is necessary to understand how these Prdm factors are activated in specific types of AML, and to elucidate their subtype-specific roles in AML development.

Hidemasa Matsuo,¹ Susumu Goyama,² Yasuhiko Kamikubo,¹ and Souichi Adachi¹

¹Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Japan; and ²Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, OH, USA.

Correspondence: adachiso@kuhp.kyoto-u.ac.jp
doi:10.3324/haematol.2015.124396

Key words: *EVI1*, *PRDM16*, acute myeloid leukemia.

Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

References

1. Marion E, Jacques D, Steven R, et al. The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 mutations share singular biological features. *Haematologica*. 2015;xxx.
2. Matsuo H, Kajihara M, Tomizawa D, et al. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. *Haematologica*. 2014;99(11):e225-227.
3. Goyama S, Kurokawa M. Evi-1 as a critical regulator of leukemic cells. *Int J Hematol*. 2010;91(5):753-757.
4. Morishita K. Leukemogenesis of the EVI1/MEL1 gene family. *Int J Hematol*. 2007;85(4):279-286.
5. Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. *Cell Stem Cell*. 2008;3(2):207-220.
6. Aguilo F, Avagyan S, Labar A, et al. Prdm16 is a physiologic regulator of hematopoietic stem cells. *Blood*. 2011;117(19):5057-5066.
7. Duhoux FF, Ameye G, Montano-Almendras CP, et al. PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. *Br J Haematol*. 2012;156(1):76-88.
8. Artinger EL, Mishra BP, Zaffuto KM, et al. An MLL-dependent network sustains hematopoiesis. *Proc Natl Acad Sci USA*. 2013;110(29):12000-12005.
9. Bagger FO, Rapin N, Theilgaard-Monch K, et al. HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis. *Nucleic Acids Res*. 2013;41(D1):D1034-1039.
10. Jo A, Mitani S, Shiba N, et al. High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. *Leukemia*. 2015 Jan 8 [Epub ahead of print]